World Journal of Hepatology · 2010 · 11 citations · 12 references
MedicineNeurologyPharmacotherapyHepatologyNeuroimmunologyNeuropathologyAntiviral TherapyDemyelinating DiseasesDemyelinating DisordersInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentChronic Viral HepatitisCombination TherapyGuillain-barré Syndrome PathogenesisInterferon Alfa TherapyNeurological EffectsPegylated Interferon AlfaSerious Adverse EventsTreatment-related Side Effects
The recommended therapy for chronic hepatitis C (CHC) infection is the combination of a Pegylated interferon and Ribavirin. Almost all such patients on combination therapy experience one or more adverse events during the course of treatment. Significant neurological side effects are rare. A few cases of Bell's Palsy, chronic inflammatory demyelinating polyneuropathy and even one case of acute demyelinating polyneuropathy with atypical features for Guillain-Barre syndrome (GBS) associated with Interferon therapy have been reported but no report of GBS with typical features has been published. We present a case report of typical GBS associated with Peginterferon alfa-2a and Ribavirin used for treatment of CHC infection.
12
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Marc G. Ghany, Doris B. Strader, David L. Thomas et al. · Hepatology · 2008 · 3K citations · Full text
The burden of hepatitis C in the United States
Hepatology · 2002 · 299 citations · Full text
Guillain-Barré Syndrome Following Influenza Vaccination
Penina Haber · JAMA · 2004 · 254 citations
Early Electrodiagnostic Findings in Guillain-Barré Syndrome
Asa J. Wilbourn · Archives of Neurology · 2001 · 234 citations
Medicine, Neurology, Neuroscience +15